Research To Practice | Oncology Videos

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer | Faculty Presentation 2: Basal Cell Carcinoma — Anna C Pavlick, DO, MBA CME information and select publications

Featuring perspectives from Dr Nikhil I Khushalani and Dr Anna C Pavlick, including the following topics: Introduction: Why Did It Take So Long? (0:00) Cutaneous Squamous Cell Carcinoma — Dr Khushalani (13:47) Basal Cell Carcinoma — Dr Pavlick (39:57) CME information and select publications

Featuring perspectives from Dr Peter C Enzinger, including the following topics: Introduction (0:00) Case: A man in his mid 60s with HER2-positive metastatic squamous cell carcinoma of the esophagus develops progressive disease after treatment with 5-FU/cisplatin/trastuzumab; PD-L1 CPS 10 — Eric H Lee, MD, PhD (12:16) Case: A man in his early 50s with HER2-negative, microsatellite stable esophageal cancer and mediastinal lymphadenopathy receives concurrent chemoradiation (CROSS trial regimen) — Jennifer L Dallas, MD (37:23) Case: A frail woman in her early 80s with past medical history of cardiac issues is diagnosed with localized gastroesophageal junction adenocarcinoma — Priya Rudolph, MD, PhD (46:58) CME information and select publications

Featuring perspectives from Dr Naval Daver, including the following topics: Introduction: Biology, Classification, p53, Magrolimab (0:00) Case: A man in his early 70s with acute myeloid leukemia (AML) with a TP53 mutation, myelodysplastic syndromes (MDS)-related changes and complex cytogenetics who received CPX-351receives azacitidine/venetoclax and is now in palliative care — Anna Halpern, MD (9:06) Case: A woman in her late 50s with multiple comorbidities and FLT3-ITD-positive AML who experienced disease progression on azacitidine/venetoclax now receives gilteritinib — Bhavana (Tina) Bhatnagar, DO (17:01) Case: A woman in her early 70s with AML with FLT3-ITD and IDH1 mutations receives a hypomethylating agent with ivosidenib — Amany R Keruakous, MD, MS (29:10) Case: A man in his early 60s with newly diagnosed MDS with ring sideroblasts receives oral decitabine/cedazuridine — Khuda Dad Khan, MD, PhD (33:54) Case: A man in his mid 60s presents with copper deficiency and ring sideroblasts; genetic analysis reveals SF3B1 and DNMT3A mutations — Rachel J Cook, MD (42:25) Case: A woman in her early 70s with a history of extensively treated follicular lymphoma develops AML and receives CPX-351 — Ranju Gupta, MD (46:05) Case: A woman in her late 70s with newly diagnosed AML receives decitabine/venetoclax with concurrent voriconazole — Rebecca L Olin, MD, MSCE (51:05) Case: A woman in her late 90s is diagnosed with multiple myeloma and del(5q) MDS — Erik Rupard, MD (54:26) Journal Club with Dr Daver (57:28) CME information and select publications

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics: Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00) Sequencing of Therapy for MCL: 2009-2025 (11:19) Cases and Questions from the Community (36:44) Case: A man in his early 80s with relapsed/refractory MCL with "brain fog" on zanubrutinib — Zanetta S Lamar, MD (56:07) CME information and select publications

Featuring an interview with Dr Joseph Mikhael, including the following topics: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00) KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47) Subgroup analysis of patients with 1q21 and other cytogenetic abnormalities in the Phase III IKEMA and ICARIA-MM studies (15:12) Results with ciltacabtagene autoleucel among patients with relapsed/refractory (R/R) MM in the CARTITUDE-1 study (26:59) CARTITUDE-4 study: Ciltacabtagene autoleucel in earlier lines of treatment for patients with lenalidomide-refractory MM (34:56) KarMMa-3 trial: Idecabtagene vicleucel for patients with R/R MM (44:20) GPRC5D-targeted CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MM (49:09) Efficacy of teclistamab for R/R MM in the MajesTEC-1 trial (53:45) Efficacy of elranatamab for R/R MM in the MagnetisMM-3 trial (58:43) Efficacy of linvoseltamab for R/R MM in the LINKER-MM1 trial (1:02:01) Talquetamab for patients with R/R MM in the MonumenTAL-1 trial (1:04:16) Future directions in the first-line management of MM (1:06:03) Strategies to improve diversity and inclusion in clinical trials (1:10:53) CME information and select publications

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Novel Approaches to Adjuvant Treatment for Localized NSCLC CME information and select publications

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: The Evolving Role of Neoadjuvant Therapy for Localized Non-Small Cell Lung Cancer (NSCLC) CME information and select publications

Featuring perspectives from Dr Jamie Chaft and Dr John V Heymach, including the following topics: Introduction: Patient Involvement in Adjuvant and Neoadjuvant Treatment Decisions (0:00) Targetable Treatment for Localized Disease (11:49) Immunotherapy for Localized Disease (35:57) CME information and select publications

Featuring an interview with Dr Michael Pishvaian, including the following topics: Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00) Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32) NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for treatment-naïve metastatic pancreatic ductal carcinoma (5:48) Perspectives on the comparative efficacy and tolerability of 2-drug and 3-drug treatment regimens in the metastatic setting; perioperative versus adjuvant therapy in locally advanced disease (9:22) Novel treatment approaches for pancreatic cancer — zolbetuximab, tumor treating fields and intra-arterial gemcitabine (14:35) Role of radiation therapy in the management of pancreatic cancer; early-phase data with novel antibody-drug conjugates (22:14) Selection of second-line therapy for metastatic pancreatic cancer (26:15) PARP inhibition for the treatment of pancreatic cancer (32:27) Investigational approaches for the treatment of KRAS mutation-positive pancreatic cancer (48:50) Vaccine-based treatment approaches under development for pancreatic cancer; palliative care strategies (52:04) CME information and select publications